Business & Economics Books:

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Paperback / softback
$317.99
Available from supplier

The item is brand new and in-stock with one of our preferred suppliers. The item will ship from a Mighty Ape warehouse within the timeframe shown.

Usually ships in 2-3 weeks

Buy Now, Pay Later with:

4 payments of $79.50 with Afterpay Learn more

Availability

Delivering to:

Estimated arrival:

  • Around 21 Jun - 3 Jul using International Courier

Description

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy discusses recently developed treatments based on molecular targets which are genetically altered in cancer cells and are essential for tumor development and survival. Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. Each chapter discusses a molecular target, such as ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1. The book's chapters are written by experts who actively work on the targets to help readers fully understand how they can be used. This is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of novel cancer therapies based on molecular targets.

Author Biography:

Dr. Vivek Asati presently work as Associate Professor in the Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga (Punjab), India. He previously worked as research associate in the Department of Pharmaceutical Sciences, Dr H.S. Gour University, Sagar (MP). He completed his PhD from the Institute of Pharmaceutical Sciences, GGV, Bilaspur. He has both research and industry experience gained at several organizations. His research areas include computer-aided drug designing and synthesis of various small molecule inhibitors. Dr. Asati has published research papers, book chapters, reviews in various peer-reviewed journals and presented own works at several national and international conferences. He Guided several M Pharm and PhD students and published patent. Dr. Ankur Vaidya did his graduation, post-graduation and PhD from Dept. of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar (M.P.) in 2004, 2008 and 2013 respectively. Dr. Vaidya has a teaching and research experience of many years and is currently working as Asst. Professor in Faculty of Pharmacy UPUMS, Saifai, Etawah (U.P.) India. Dr. Ankur has a key research interest in discovery of new anticancer agents with novel targets and published dozens outstanding publications in various International journals. Dr Vaidya has credited as reviewer of international journals of repute in the field of Pharmaceutical sciences. Dr. Ankur has guided several postgraduate theses and was also the recipient of AICTE-NDF (National Doctorate Fellowship) fellowship for PhD research project. Dr. Vaidya has published nternational book chapters, one International book authored and 1 national book. Dr. Ankur has participated/presented in various National and International conferences.
Release date Australia
April 15th, 2024
Audience
  • Professional & Vocational
Contributors
  • Edited by Ankur Vaidya
  • Edited by Vivek Asati
Pages
502
ISBN-13
9780323961219
Product ID
36186716

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

Filed under...